Short answer
OptimizeRx Corp (OPRX) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders approved 1,000,000 additional shares for equity awards under the 2021 Equity Incentive Plan.
OptimizeRx Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Shareholders approved 1,000,000 additional shares for equity awards under the 2021 Equity Incentive Plan
- Total shares available increased to 5,450,000, expanding potential employee and executive compensation capacity
- Potential dilution for existing shareholders, depending on future award grants and share issuance
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All seven director nominees elected, with votes for ranging from 8,092,151 to 12,160,558
- Executive compensation approved on an advisory basis, with 11,660,549 votes in favor
- Equity Plan expanded by 1,000,000 shares, increasing potential equity-based compensation dilution
- Evergreen provision rejected, limiting automatic annual increases in shares available for equity awards
- Grant Thornton ratified as 2026 independent auditor, with 15,750,329 votes in favor
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OptimizeRx Corp 8-K filings
Get the next OPRX 8-K as it lands
Follow OPRX for push alerts, or ask the research agent what this filing means.